BR0206852A - Conjugados de polìmero de neublastina e métodos para uso dos mesmos - Google Patents
Conjugados de polìmero de neublastina e métodos para uso dos mesmosInfo
- Publication number
- BR0206852A BR0206852A BR0206852-4A BR0206852A BR0206852A BR 0206852 A BR0206852 A BR 0206852A BR 0206852 A BR0206852 A BR 0206852A BR 0206852 A BR0206852 A BR 0206852A
- Authority
- BR
- Brazil
- Prior art keywords
- neublastin
- methods
- polymer conjugates
- conjugates
- therapeutic
- Prior art date
Links
- 102100026376 Artemin Human genes 0.000 title abstract 5
- 101000785776 Homo sapiens Artemin Proteins 0.000 title abstract 3
- 229920000642 polymer Polymers 0.000 title abstract 3
- 230000002035 prolonged effect Effects 0.000 abstract 2
- 230000001225 therapeutic effect Effects 0.000 abstract 2
- 230000004071 biological effect Effects 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 125000003827 glycol group Chemical group 0.000 abstract 1
- 229920001515 polyalkylene glycol Polymers 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Zoology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Psychology (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biophysics (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26607101P | 2001-02-01 | 2001-02-01 | |
| PCT/US2002/002319 WO2002060929A2 (en) | 2001-02-01 | 2002-01-25 | Polymer conjugates of neublastin and methods of using same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0206852A true BR0206852A (pt) | 2005-05-03 |
Family
ID=23013042
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0206852-4A BR0206852A (pt) | 2001-02-01 | 2002-01-25 | Conjugados de polìmero de neublastina e métodos para uso dos mesmos |
Country Status (35)
| Country | Link |
|---|---|
| EP (2) | EP1862475A1 (https=) |
| JP (2) | JP4259868B2 (https=) |
| KR (2) | KR100872807B1 (https=) |
| CN (1) | CN1500095B (https=) |
| AR (1) | AR035077A1 (https=) |
| AT (1) | ATE365748T1 (https=) |
| AU (1) | AU2002247037B2 (https=) |
| BG (1) | BG66393B1 (https=) |
| BR (1) | BR0206852A (https=) |
| CA (1) | CA2436407C (https=) |
| CY (1) | CY1106886T1 (https=) |
| CZ (1) | CZ20032080A3 (https=) |
| DE (1) | DE60220879T2 (https=) |
| DK (1) | DK1355936T3 (https=) |
| EA (1) | EA009771B1 (https=) |
| EE (1) | EE05537B1 (https=) |
| ES (1) | ES2289091T3 (https=) |
| GE (1) | GEP20063916B (https=) |
| HU (1) | HU228973B1 (https=) |
| IL (2) | IL156941A0 (https=) |
| IS (1) | IS2867B (https=) |
| MX (1) | MXPA03006805A (https=) |
| MY (1) | MY143685A (https=) |
| NO (1) | NO332150B1 (https=) |
| NZ (1) | NZ527863A (https=) |
| PL (1) | PL211162B1 (https=) |
| PT (1) | PT1355936E (https=) |
| RS (1) | RS50857B (https=) |
| SG (1) | SG149685A1 (https=) |
| SI (1) | SI1355936T1 (https=) |
| SK (1) | SK288123B6 (https=) |
| TR (1) | TR200301208T2 (https=) |
| UA (2) | UA100967C2 (https=) |
| WO (1) | WO2002060929A2 (https=) |
| ZA (1) | ZA200305733B (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7442370B2 (en) | 2001-02-01 | 2008-10-28 | Biogen Idec Ma Inc. | Polymer conjugates of mutated neublastin |
| DK1355936T3 (da) * | 2001-02-01 | 2007-10-29 | Biogen Idec Inc | Polymerkonjugater af neublastin og fremgangsmåder til anvendelse af samme |
| US7276580B2 (en) | 2001-03-12 | 2007-10-02 | Biogen Idec Ma Inc. | Neurotrophic factors |
| CN1525866B (zh) * | 2001-03-28 | 2013-05-29 | 比奥根艾迪克Ma公司 | 神经胚活素多肽的治疗作用 |
| PT3025726T (pt) * | 2002-01-18 | 2020-01-09 | Biogen Ma Inc | Compostos do polímero polialquileno e utilizações dos mesmos |
| EA008743B1 (ru) * | 2003-01-31 | 2007-08-31 | Байоджен Айдек Ма Инк. | Полимерные конъюгаты мутантного неубластина |
| WO2004094592A2 (en) | 2003-04-18 | 2004-11-04 | Biogen Idec Ma Inc. | Polymer-conjugated glycosylated neublastin |
| NZ544263A (en) | 2003-06-10 | 2009-04-30 | Nsgene As | Improved secretion of neublastin |
| US7598059B2 (en) | 2003-10-02 | 2009-10-06 | Biogen Idec Ma Inc. | Neublastin expression constructs |
| CA2577690C (en) * | 2004-08-19 | 2013-08-06 | Biogen Idec Ma Inc. | Refolding transforming growth factor beta family proteins |
| DK1786454T3 (da) | 2004-08-19 | 2010-09-06 | Biogen Idec Inc | Neublastinvarianter |
| TWI501774B (zh) | 2006-02-27 | 2015-10-01 | Biogen Idec Inc | 神經性病症之治療 |
| ES2450065T3 (es) * | 2006-03-01 | 2014-03-21 | Biogen Idec Ma Inc. | Composiciones y métodos para la administración de proteínas de la familia de ligandos del GDNF |
| CA2663300C (en) | 2006-09-15 | 2014-10-07 | Creabilis Therapeutics S.P.A. | Polymer conjugates of box-a of hmgb1 and box-a variants of hmgb1 |
| EP2142205B1 (en) * | 2007-05-01 | 2014-04-02 | Biogen Idec MA Inc. | Neublastin peptides for use in increasing vascularisation in tissue with impaired blood flow |
| HUE035685T2 (en) * | 2011-11-02 | 2018-05-28 | Hoffmann La Roche | Overload and elute chromatography |
| RU2488635C1 (ru) * | 2012-03-22 | 2013-07-27 | Государственное бюджетное образовательное учреждение высшего профессионального образования Первый Московский государственный медицинский университет им. И.М. Сеченова Министерства здравоохранения и социального развития Российской Федерации (ГБОУ ВПО Первый МГМУ им. И.М. Сеченова Минздравсоцразвития | Способ получения рекомбинантного антиангиогенного полипептида |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6472178B1 (en) * | 1998-02-27 | 2002-10-29 | Regeneron Pharmaceuticals, Inc. | Nucleic acids encoding a modified ciliary neurotrophic factor and method of making thereof |
| US5770577A (en) * | 1994-11-14 | 1998-06-23 | Amgen Inc. | BDNF and NT-3 polypeptides selectively linked to polyethylene glycol |
| US6593133B1 (en) * | 1998-07-06 | 2003-07-15 | Nsgene A/S | Neurotrophic factors |
| WO2000034475A2 (en) * | 1998-12-09 | 2000-06-15 | Amgen Inc. | Grnf4, a gdnf-related neurotrophic factor |
| DK1355936T3 (da) * | 2001-02-01 | 2007-10-29 | Biogen Idec Inc | Polymerkonjugater af neublastin og fremgangsmåder til anvendelse af samme |
-
2002
- 2002-01-25 DK DK02714792T patent/DK1355936T3/da active
- 2002-01-25 KR KR1020037010127A patent/KR100872807B1/ko not_active Expired - Fee Related
- 2002-01-25 EP EP07110666A patent/EP1862475A1/en not_active Withdrawn
- 2002-01-25 EE EEP200300355A patent/EE05537B1/xx not_active IP Right Cessation
- 2002-01-25 HU HU0500637A patent/HU228973B1/hu not_active IP Right Cessation
- 2002-01-25 TR TR2003/01208T patent/TR200301208T2/xx unknown
- 2002-01-25 DE DE60220879T patent/DE60220879T2/de not_active Expired - Lifetime
- 2002-01-25 BR BR0206852-4A patent/BR0206852A/pt not_active Application Discontinuation
- 2002-01-25 CZ CZ20032080A patent/CZ20032080A3/cs unknown
- 2002-01-25 KR KR1020087022638A patent/KR100960063B1/ko not_active Expired - Fee Related
- 2002-01-25 CA CA2436407A patent/CA2436407C/en not_active Expired - Fee Related
- 2002-01-25 NZ NZ527863A patent/NZ527863A/en not_active IP Right Cessation
- 2002-01-25 CN CN028077539A patent/CN1500095B/zh not_active Expired - Fee Related
- 2002-01-25 IL IL15694102A patent/IL156941A0/xx unknown
- 2002-01-25 JP JP2002561497A patent/JP4259868B2/ja not_active Expired - Fee Related
- 2002-01-25 PL PL372101A patent/PL211162B1/pl unknown
- 2002-01-25 SG SG200504719-6A patent/SG149685A1/en unknown
- 2002-01-25 EP EP02714792A patent/EP1355936B1/en not_active Expired - Lifetime
- 2002-01-25 GE GE5240A patent/GEP20063916B/en unknown
- 2002-01-25 UA UAA200802148A patent/UA100967C2/ru unknown
- 2002-01-25 UA UA2003088104A patent/UA82983C2/ru unknown
- 2002-01-25 AR ARP020100279A patent/AR035077A1/es not_active Application Discontinuation
- 2002-01-25 ES ES02714792T patent/ES2289091T3/es not_active Expired - Lifetime
- 2002-01-25 SK SK971-2003A patent/SK288123B6/sk not_active IP Right Cessation
- 2002-01-25 AT AT02714792T patent/ATE365748T1/de active
- 2002-01-25 EA EA200300852A patent/EA009771B1/ru not_active IP Right Cessation
- 2002-01-25 RS YUP-610/03A patent/RS50857B/sr unknown
- 2002-01-25 PT PT02714792T patent/PT1355936E/pt unknown
- 2002-01-25 WO PCT/US2002/002319 patent/WO2002060929A2/en not_active Ceased
- 2002-01-25 SI SI200230580T patent/SI1355936T1/sl unknown
- 2002-01-25 MX MXPA03006805A patent/MXPA03006805A/es active IP Right Grant
- 2002-01-25 AU AU2002247037A patent/AU2002247037B2/en not_active Ceased
- 2002-02-04 MY MYPI20020368A patent/MY143685A/en unknown
-
2003
- 2003-07-15 IL IL156941A patent/IL156941A/en not_active IP Right Cessation
- 2003-07-17 IS IS6879A patent/IS2867B/is unknown
- 2003-07-24 ZA ZA2003/05733A patent/ZA200305733B/en unknown
- 2003-08-01 NO NO20033441A patent/NO332150B1/no not_active IP Right Cessation
- 2003-08-19 BG BG108111A patent/BG66393B1/bg unknown
-
2007
- 2007-09-21 CY CY20071101225T patent/CY1106886T1/el unknown
-
2008
- 2008-10-28 JP JP2008277469A patent/JP4423338B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0206852A (pt) | Conjugados de polìmero de neublastina e métodos para uso dos mesmos | |
| BR9915542A (pt) | Conjugados de polìmero de interferon beta-1a e usos | |
| BRPI0508455A (pt) | muteìnas de interleucina-2 combinatórias | |
| BR0008840A (pt) | Derivados de camptotecina tendo atividade antitumoral | |
| BRPI9917007B8 (pt) | azabicicloalcanos como moduladores de ccr5, composição farmacêutica contendo os mesmos, bem como seu uso | |
| BR9914360A (pt) | N-aralquilaminotetralinas como ligandos para oreceptor neuropeptìdeo yy5 | |
| BR0211546A (pt) | Composição farmacêutica e/ou de diagnóstico e uso de microrganismo ou célula | |
| BRPI0510428A (pt) | composições tópicas de metadona e processos para utilização das mesmas | |
| MXPA02006679A (es) | Composicion farmaceutica. | |
| BRPI0407882A (pt) | conjugados de polìmero-porção de fator viii | |
| BR0102040A (pt) | Uso de paclitaxel estabilizado com albumina para preparação de uma droga para o tratamento de tumores sólidos e a droga desse modo obtida | |
| GT199900131A (es) | Derivados del acido hidroxi-pipecolato hidroxamico. | |
| BRPI0613005A8 (pt) | uso de polipeptídeos de aprotinina como veículos em conjugados farmacêuticos. | |
| BR9814276A (pt) | Antìgenos de superfìcie | |
| BR0108173A (pt) | Composições farmacêuticas de toxina de botulina | |
| BRPI0007487B8 (pt) | difenil-uréias substituídas com w-carbóxi-arilas como inibidores de raf cinase | |
| CY1112682T1 (el) | Ενεργες παραλλαγες της πρωτεϊνης προσδεσης il-18 και ιατρικες χρησεις αυτων | |
| BR9910573A (pt) | Compostos antipicornavirais, preparação e uso dos mesmos | |
| BR0008228A (pt) | Composições de n-benzoil estaurosporinaespontaneamente dispersìveis | |
| BR0315437A (pt) | Composição para o tratamento dos cabelos, usos da mesma e método para o tratamento dos cabelos | |
| BR9911349A (pt) | Genes para a biossìntese de epotilonas | |
| BR0311866A (pt) | Composições de saponinas ou sapogeninas para terapia de câncer | |
| ATE291586T1 (de) | Humanes antibiotisches protein | |
| ATE331730T1 (de) | Neue depsipeptid-verbindung | |
| BRPI0416870A (pt) | composições anticáncer sinergìticas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25D | Requested change of name of applicant approved |
Owner name: BIOGEN IDEC MA, INC. (US) Free format text: ALTERADO DE: BIOGEN, INC. |
|
| B25D | Requested change of name of applicant approved |
Owner name: BIOGEN IDEC MA INC. (US) Free format text: ALTERADO DE: BIOGEN IDEC MA, INC. |
|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements | ||
| B15K | Others concerning applications: alteration of classification |
Free format text: PROCEDIMENTO AUTOMATICO DE RECLASSIFICACAO. AS CLASSIFICACOES IPC ANTERIORES ERAM: C07K 14/475; C12N 15/12; A61K 47/48; A61K 38/18. Ipc: C07K 14/475 (2006.01), A61K 47/60 (2017.01), A61K Ipc: C07K 14/475 (2006.01), A61K 47/60 (2017.01), A61K |